Company news
Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) news
Indivior Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 17, 2026: Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Press releases & updates
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
September 17, 2026
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
August 3, 2026
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
July 23, 2026
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
May 20, 2026
Indivior Announces $175 Million Accelerated Share Repurchase
May 4, 2026
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
April 30, 2026
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
April 24, 2026
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
April 16, 2026
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
April 9, 2026
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
April 8, 2026
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
March 31, 2026
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
March 17, 2026
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
March 11, 2026
Indivior Announces Proposed Convertible Senior Notes Offering
March 11, 2026
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
March 11, 2026
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
February 25, 2026
Indivior to Participate in Upcoming Investor Conferences
February 24, 2026
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26??
January 29, 2026
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
January 28, 2026
Indivior Announces Completion of Redomiciliation to the United States
January 25, 2026
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
January 7, 2026
Indivior Announces Inclusion in the S&P SmallCap 600® Index
December 21, 2025
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
December 17, 2025
Indivior Concludes Legacy U.S. Department of Justice Matter
November 20, 2025
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 19, 2025
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
November 3, 2025
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
October 29, 2025
Indivior to Participate in the Stifel 2025 Healthcare Conference
October 28, 2025
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
October 16, 2025
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
October 14, 2025
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
October 1, 2025
Addex Appoints Bank of New York Mellon as Depositary Bank
September 23, 2025
Indivior to Participate in Upcoming Investor Events
August 20, 2025
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
July 30, 2025
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
July 24, 2025
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
July 23, 2025
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
July 17, 2025
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
July 7, 2025
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
June 29, 2025
Indivior Appoints Tony Kingsley to the Board of Directors
June 23, 2025
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
June 19, 2025
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
June 1, 2025
Indivior Announces Patrick Barry as Chief Commercial Officer
May 26, 2025
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
May 1, 2025
Indivior Announces Q1 2025 Financial Results
April 23, 2025
Indivior Announces Further Changes to Board of Directors
March 3, 2025
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
February 26, 2025
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
February 23, 2025
Indivior Announces FY and Q4 2024 Financial Results
February 19, 2025
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
February 11, 2025